Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Study Title
A Phase 1, Single Dose, Parallel Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TV-44749, Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use, in Chinese Patients with Schizophrenia
Teva Identifier
TV44749-PK-10188
ClinicalTrials.gov Identifier
NCT06253546
Study Status
Completed
Trial Condition(s)
Schizophrenia
Interventions
TV44749 | Oral Olanzapine
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
psychiatry-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult
Age Range
18 Years to 64 Years
Trial Duration
March 28, 2024 - June 12, 2025
Phase
Phase 1

Additional info

Study Type

Interventional